

Supplementary material has been published as submitted. It has not been copyedited or typeset by Journal of Plastic Surgery and Hand Surgery.

Supplementary Table 1 PRISMA checklist for systematic review

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	3
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4, 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	4, 5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	4, 5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	NA
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	NA
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	NA

Section and Topic	Item #	Checklist item	Location where item is reported
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	NA
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	NA
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	NA
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	NA
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	5
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	5
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	NA
Study characteristics	17	Cite each included study and present its characteristics.	6, 7, Supp. File
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	8
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	6, 7, Supp. File
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	6, 7
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	6, 7
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	6, 7
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	8
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	NA
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	8, 9, 10
	23b	Discuss any limitations of the evidence included in the review.	8, 9, 10
	23c	Discuss any limitations of the review processes used.	8, 9, 10
	23d	Discuss implications of the results for practice, policy, and future research.	8, 9, 10

Section and Topic	Item #	Checklist item	Location where item is reported
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	3
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	3
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	10
Competing interests	26	Declare any competing interests of review authors.	10
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	10

*Supplementary Table 2 Search Strategy and search results for each database*

Database	Search Term	N of Results
PubMed	(Basal cell carcinoma[title/abstract] OR BCC[title/abstract] OR SCC[title/abstract] OR cSCC[title/abstract] OR squamous cell carcinoma[title/abstract] OR melanom*[title/abstract] OR cancer*[title/abstract] OR carcinom*[title/abstract] OR malign*[title/abstract] OR tumor*[title/abstract] OR tumour*[title/abstract]) AND burn[title/abstract] AND case[title/abstract]	412
Scopus	("basal cell carcinoma" OR bcc OR scc OR csc OR "squamous cell carcinoma" OR melanom* OR cancer* OR carcinom* OR malign* OR tumor* OR tumour*) AND burn AND case	2,911

	In title, abstract, keywords	
WOS	("basal cell carcinoma" OR bcc OR scc OR csc OR "squamous cell carcinoma" OR melanom* OR cancer* OR carcinom* OR malign* OR tumor* OR tumour*) AND burn AND case In all fields	2,092
Total		5,415

Supplementary Table 3 Individual Study characteristics and risk of bias score

Reference ID	Design	Country	No. of Cases Developed cancer after Burn	Age/Average Age (in years)	Gender/No. of Males	Latency period/Average (in years)	QA Score
<b>Mishell et al. 1919</b>	Case Report/Series	USA	1	57	Male	0.25	Fair
<b>Ghosh et al. 1966</b>	Case Report/Series	UK	1	60	Male	26	Good
<b>Sanjay et al. 2023</b>	Case Report/Series	India	1	62	Male	52	Good
<b>Nishimoto et al, 1996</b>	Case Report/Series	Japan	1	64	Male	25	Good
<b>Kim et al, 2018</b>	Case Report/Series	Korea	1	28	Male	10	Fair
<b>Vanhooteghem et al, 2018</b>	Case Report/Series	Belgium	1	66	Female	55	Fair
<b>Xiao et al 2018</b>	Case Control	China	31	52.2	16 Males	42.9	Fair
<b>CelikGz' et al, 1997</b>	Case Report/Series	Turkey	1	21	Male	3	Fair
<b>Goswami et al. 2023</b>	Case Report/Series	india	1	28	Female	5.67	Good

<b>Pelia et al, 1999</b>	Case Report/Series	Italy	1	59	Male	0.125	Bad
<b>Kannan et al, 2010</b>	Case Report/Series	UK	1	46	Male	3	Good
<b>Chang et al. 2014</b>	Case Report/Series	USA	2	51	1 Male	0.3125	Good
<b>Love et al, 2000</b>	Case Report/Series	Australia	1	14	Male	0.27	Good
<b>Daya et al,2020</b>	Case Report/Series	South Africa	1	13	Male	10	Good
<b>Rio et al, 2022</b>	Case Report/Series	Spain	1	48	Male	0.58	Good
<b>Sabin et al, 2004</b>	Case Report/Series	USA	1	69	Male	30	Good
<b>Fancher et al, 2015</b>	Case Report/Series	USA	1	67	Male	50	Good
<b>Pertusi et al, 2017</b>	Case Report/Series	Italy	1	75	Female	50	Good
<b>Ghorbani et al, 1996</b>	Case Report/Series	Michigan	1	3	Female	0.5	Fair
<b>Sumulong et al, 2023</b>	Case Report/Series	Thailand	1	60	Male	12	Good
<b>Mohammadi et al, 2017</b>	Case Report/Series	Iran	1	65	Male	0.06	Good
<b>Mendonca et al, 2005</b>	Case Report/Series	UK	1	39	Male	34	Fair
<b>YuÈcel et al, 2000</b>	Case Report/Series	Turkey	2	48.5	1 Male	36	Good
<b>Chang et al, 2011</b>	Case Report/Series	USA	1	55	Male	25	Good
<b>Dogan et al, 2019</b>	Case Report/Series	USA	1	70	Female	2	Good

<b>Fix et al, 2017</b>	Case Report/Series	USA	1	78	Male	many years	Good
<b>Ergu'n et al, 2011</b>	Case Report/Series	Japan	1	66	Male	65	Good
<b>Hiscutt et al, 2008</b>	Case Report/Series	UK	1	50	Male	37	Good
<b>Sánchez-García et al, 2020</b>	Case Report/Series	Spain	1	92	Female	85	Good
<b>Stromberg et al, 1990</b>	Case Report/Series	USA	1	65	Male	20	Good
<b>Camacho et al, 1999</b>	Case Report/Series	Spain	1	75	Male	2	Fair
<b>Ng et al, 2006</b>	Case Report/Series	UK	1	80	Male	0.25	Fair
<b>Koga et al. 1997</b>	Case Report/Series	japan	1	74	Male	50	Fair
<b>Martín et al. 2005</b>	Case Report/Series	Spain	1	72	Female	2	Fair
<b>Ünverdi et al. 2020</b>	Case Report/Series	Turkey	1	52	Male	50	Fair
<b>WHITE et al. 1983</b>	Case Report/Series	USA	1	57	Female	51	Fair
<b>Grimaux et al. 2017</b>	Case Report/Series	France	1	76	Male	71	Good
<b>Cobey et al. 2006</b>	Case Report/Series	USA	1	32	Male	15	Good
<b>Huang et al 2010</b>	Case Report/Series	Taiwan	11	47	5 Males	27.3	Fair
<b>PHILLIPS et al. 1998</b>	Case Report/Series	N/A	1	56	Male	40	Good
<b>GERNER et al. 1973</b>	Case Report/Series	USA	1	38	Male	33	Good

<b>Mosborg et al. 1988</b>	Case Report/Series	USA	2	33	Male	16.8	Good
<b>Tiiregtin, et al. 1997</b>	Case Report/Series	Turkey	1	61	Female	56	Good
<b>Pratt et al. 2000</b>	Case Report/Series	USA	2	40.5	Male	2	Good
<b>OËzyazgana,et al. 1999</b>	Case Report/Series	Turkey	1	39	Female	20	Fair
<b>Gargan et al. 1988</b>	Case Report/Series	USA	1	49	Female	3	Good
<b>Abbas et al. 1988</b>	Case Report/Series	Saudi Arabia	1	22	Male	14	Good
<b>SARMA et al. 1985</b>	Case Report/Series	USA	1	60	Male	30	Good
<b>Dinato et al. 2011</b>	Case Report/Series	brazil	1	29	Male	16	Fair
<b>XIANG et al 2019</b>	Case Control	China	140	53.3	88 Males	28.8	Fair
<b>Matsui et al. 2020</b>	Case Report/Series	japan	1	81	Male	80	Good
<b>Baroni et al, 2011</b>	Case Report/Series	Italy	1	68	Female	40	Fair
<b>Agarwal et al, 2020</b>	Case Report/Series	India	1	44	Male	18	Good
<b>Sasaki et al, 2023</b>	Case Report/Series	japan	1	72	Male	53	Good
<b>Bozkurt et al, 2010</b>	Case Report/Series	Turkey	16	57.1	10 Males	30	fair
<b>Fukuzumi et al. 2014</b>	Case Report/Series	japan	1	70	Male	-	good
<b>Suzannah et al. 2006</b>	Case Report/Series	USA	2	45	Female	45	fair

<b>Min et al. 2017</b>	Case Report/Series	Korea	1	73	Female	70	good
<b>Jong et al. 2009</b>	Case Report/Series	Korea	1	43	Male	35	good
<b>Aya et al 2004</b>	Case Report/Series	Japan	1	68	Female	62	good
<b>JIN et al. 2006</b>	Case Report/Series	USA	1	61	Female	59	good
<b>Adam et al 2010</b>	Case Report/Series	USA	1	74	Female	-	fair
<b>Esra et al 2004</b>	Case Report/Series	Turkey	1	23	Male	11	fair
<b>Ali et al 2013</b>	Case Report/Series	Iran	1	54	Male	0.097	good
<b>E.ICHIKAWA et al 2000</b>	Case Report/Series	Japan	1	72	Female	32	good
<b>kusum et al 2009</b>	Case Report/Series	India	1	29	Female	9	fair
<b>Steven et al 2007</b>	Case Report/Series	Austria	1	80	Female	40	good
<b>Elaine et al 2018</b>	Case Report/Series	USA	1	32	Male	0.058	good
<b>A. Rico et al 1995</b>	Case Report/Series	Spain	1	17	Male	0.075	good
<b>Eduardo et al 2007</b>	Case Report/Series	Brazil	1	48	Male	17	fair
<b>Ilkin et al 2011</b>	Case Report/Series	Turkey	1	72	Female	70	good
<b>Nandini et al 2021</b>	Case Report/Series	India	1	32	Male	5	good
<b>Wendie et al 2012</b>	Case Report/Series	USA	1	56	Female	10	good

<b>Babikir et al 2018</b>	Case Report/Series	USA	1	63	Male	30	fair
<b>Lawrence et al 1969</b>	Case Report/Series	USA	1	68	Female	0.5	good
<b>Neil et al 1985</b>	Case Report/Series	USA	1	68	Female	63	fair
<b>T.NARA et al 2003</b>	Case Report/Series	Japan	1	42	Male	24	good
<b>Pascale et al 2017</b>	Case Report/Series	Brazil	1	59	Male	32	good
<b>Yayoi et al 2009</b>	Case Report/Series	Japan	1	61	Male	-	good
<b>Sophia et al 2021</b>	Case Report/Series	USA	1	-	Male	-	fair
<b>Khursheed et al 2012</b>	Case Report/Series	India	1	36	Female	33	good
<b>Seok et al 2009</b>	Case Report/Series	Korea	1	58	Male	10	good
<b>E. Vandeweyer et al 2002</b>	Case Report/Series	Belgium	1	72	Female	46	good
<b>Jefrey et al 1991</b>	Case Report/Series	USA	1	49	Male	40	good
<b>M. Al-Zacko et al 2013</b>	Case Report/Series	Iraq	27	42.7	18 Males	27.6	good
<b>Ikeda et al 1995</b>	Case Report/Series	Japan	1	47	Male	37	good
<b>Anca et al 2020</b>	Case Report/Series	Romania	3	68.7	2 Males	-	fair
<b>H. Ozercan et al 2004</b>	Case Report/Series	Turkey	1	36	Male	-	fair
<b>K. Ugur et al 1999</b>	Case Report/Series	Turkey	1	23	Female	20	fair

<b>T.YAMAMURA 1983</b>	Case Report/Seri es	Japan	1	29	Male	25	good
<b>W, M. Cocke et al 1993</b>	Case Report/Seri es	USA	1	74	Male	71	good
<b>Gwang et al 2004</b>	Case Report/Seri es	Korea	1	38	Male	20	good
<b>M.Akiyama et al 1997</b>	Case Report/Seri es	Japan	1	55	Male	51	good
<b>M. F. MUHLEMANN 1982</b>	Case Report/Seri es	UK	1	59	Male	-	good
<b>J. H. Stilwell et al 1982</b>	Case Report/Seri es	UK	1	47	Male	-	good
<b>J. D. NANCARROW 1979</b>	Case Report/Seri es	UK	1	44	Female	6	fair
<b>PAUL et al 2001</b>	Case Report/Seri es	USA	1	67	Female	60	good
<b>George X et al 1974</b>	Case Report/Seri es	USA	1	47	Male	9	good
<b>Hermann et al 2000</b>	Case Report/Seri es	USA	1	87	Female	71	fair
<b>I. E. Gamatsi et al 2000</b>	Case Report/Seri es	UK	1	19	Female	0.5	good
<b>Ufuk Durgun et al 2021</b>	Case Report/Seri es	Turkey	1	51	Female	5	fair
<b>Han Byul Lee et al 2018</b>	Case Report/Seri es	south Korea	1	67	Male	30	good
<b>Shusuke Uchida et al 2016</b>	Case Report/Seri es	Japan	1	78	Male	73	good
<b>WILLIAM et al 1957</b>	Case Report/Seri es	USA	1	55	Male	30	good
<b>J. R. Scott et al 1996</b>	Case Report/Seri es	UK	1	57	Female	55	fair

<b>RATNAKISHORE et al 2008</b>	Case Report/Series	USA	1	54	Male	0.92	fair
<b>Suruchi et al 2023</b>	Case Report/Series	India	1	62	Male	52	good
<b>Aroma et al 2023</b>	Case Report/Series	Pakistan	1	22	Male	14	good
<b>Das et al. (2009)</b>	Case Report/Series	India	1	55	Female	21	Fair
<b>Ghalambor 2007</b>	Case Report/Series	Iran	148	46	119 Males	6.25	Fair
<b>Baus 2021</b>	Case Report/Series	France	4	39.75	Male	16.25	Good
<b>de la Paz (2020)</b>	Case Report/Series	Philippines	1	30	Female	29.5	Good
<b>Uzunismail et al. (1995)</b>	Case Report/Series	Turkey	1	60	Female	-	Good
<b>Fernandes et al. (2018)</b>	Case Report/Series	Portugal	1	25	Female	-	Fair
<b>Sisti et al. (2018)</b>	Case Report/Series	Italy	1	51	Male	48	Good
<b>WONG et al. (2003)</b>	Case Report/Series	USA	1	72	Female	65	Good
<b>Suhag et al. (2005)</b>	Case Report/Series	India	1	50	Male	25	Fair
<b>Ranganathan (2015)</b>	Case Report/Series	India	1	52	Male	20	Good
<b>Bloemsma (2008)</b>	Case Report/Series	Netherlands	1	68	Male	67.987	Good
<b>Johnson (2013)</b>	Case Report/Series	USA	1	57	Male	49	Good
<b>Ozek 2001</b>	Case Report/Series	Turkey	4	48.75	1 Male	34.38	Good

<b>Atiyeh (2005)</b>	Case Report/Series	Lebanon	1	68	Male	20	Good
<b>Wroński (2014)</b>	Case Report/Series	Poland	1	70	Male	15	Good
<b>Partanen (2012)</b>	Case Report/Series	Finland	1	90	Male	86	Good
<b>Copcu (2002)</b>	Case Report/Series	Turkey	1	54	Male	33	Good
<b>Garcia-Marín 2014</b>	Case Report/Series	Spain	2	63.5	Male	10	Good
<b>Tian (2021)</b>	Case Report/Series	china	1	50	Male	39	Good
<b>Iqbal (2015)</b>	Case Report/Series	UK	1	67	Female	61	Good
<b>Hatzis (2007)</b>	Case Report/Series	TX	1	76	Male	48	Good
<b>Bauk 2006</b>	Case Report/Series	Brazil	12	61.3	7 Males	23.7	Fair
<b>Chiang (2006)</b>	Case Report/Series	Taiwan	1	47	Male	30	Good
<b>Jamabo 2004</b>	Case Report/Series	Nigeria	3	29.3	2 Males	21.7	Good
<b>Asuquo 2007</b>	Case Report/Series	Nigeria	1	31	Male	16	Good
<b>Olaitan (2007)</b>	Case Report/Series	Nigeria	1	18	Female	2	Good
<b>BOZKURT (2009)</b>	Case Report/Series	Turkey	2	44.5	Male	24.5	Good
<b>Tobin 2014</b>	Case Report/Series	US	1	80	Male	50	Fair
<b>Schnell (2009)</b>	Case Report/Series	USA	1	57	Male	46	Good

<b>Ostojić (2022)</b>	Case Report/Series	Serbia	1	67	Male	46	Good
<b>Ribero (2012)</b>	Case Report/Series	Italy	1	64	Male	13	Good
<b>Chi (2001)</b>	Case Report/Series	China	1	62	Male	3	Good
<b>Serras (2019)</b>	Case Report/Series	Portugal	1	74	Female	14	Good
<b>Balakrishnan (1994)</b>	Case Report/Series	USA	1	40	Male	0.25	Fair
<b>Basbuga (2011)</b>	Case Report/Series	Turkey	1	69	Female	-	Good
<b>Stone (1970)</b>	Case Report/Series	USA	1	30	Female	22	Good
<b>Bagazgoitia (2009)</b>	Case Report/Series	Spain	1	55	Male	50	Good
<b>Ikeda (1995)</b>	Case Report/Series	Japan	1	47	Male	37	Good
<b>HWANG (2004)</b>	Case Report/Series	korea	1	58	Male	37	Good
<b>Zuo (2014)</b>	Case Report/Series	Canada	1	61	Male	57	Good
<b>Atzenia (2009)</b>	Case Report/Series	Italy	1	44	Female	38	Good
<b>Cantwell (2018)</b>	Case Report/Series	Australia	1	78	Male	38	Good
<b>WOLFE (2012)</b>	Case Report/Series	USA	1	52	Male	27	Good
<b>Hobbs (2019)</b>	Case Report/Series	USA	2	65	1 Male	0.114	Good
<b>Efendizade (2018)</b>	Case Report/Series	USA	1	33	Male	23	Good

<b>Ito (2011)</b>	Case Report/Series	Japan	1	93	Male	-	Good
<b>HONG (2013)</b>	Case Report/Series	korea	1	64	Female	-	Fair
<b>Kibbi (2018)</b>	Case Report/Series	USA	1	65	Male	-	Good
<b>Lee (1991)</b>	Case Report/Series	USA	1	60	Male	54	Good
<b>Qi 2012</b>	Case Report/Series	malaysia	1	62	Male	61	Good
<b>Sengul 2009</b>	Case Report/Series	Turkey	1	64	Male	57	Good
<b>Onah 2010</b>	Case Report/Series	Nigeria	1	12	Female	11	Good
<b>Nayak 2014</b>	Case Report/Series	USA	1	68	Female	16	Good
<b>White 2002</b>	Case Report/Series	USA	1	74	Female	73	Fair
<b>Park 2022</b>	Case Report/Series	Korea	1	52	Male	40	Good
<b>Nagaraj 2001</b>	Case Report/Series	Bahrain	1	26	Female	-	Fair
<b>Jain 2015</b>	Case Report/Series	India	1	50	Female	45	Fair
<b>Singh 2013</b>	Case Report/Series	India	1	27	Female	20	Fair
<b>Mangeret 2020</b>	Case Report/Series	Switzerland	1	0.48	Female	0.046	Fair
<b>Aron 1989</b>	Case Report/Series	Libya	20	47.45	14 Males	23.2	Fair
<b>Bhasme 2022</b>	Case Report/Series	India	1	18	Male	15	Good

<b>Amoh 2012</b>	Case Report/Series	Japan	1	35	Male	-	Good
<b>Morihara 2007</b>	Case Report/Series	Japan	1	64	Female	13	Good
<b>Koh 2014</b>	Case Report/Series	Korea	1	65	Female	35	Good
<b>Cherkaoui 2022</b>	Case Report/Series	Morocco	1	0.75	Female	-	Fair
<b>Cheo 2015</b>	Case Report/Series	Korea	1	53	Female	-	Good
<b>Baig 2016</b>	Case Report/Series	India	1	38	Female	20	Good
<b>Alkrekshi 2019</b>	Case Report/Series	USA	1	54	Male	47	Good
<b>Sethi 2012</b>	Case Report/Series	India	1	22	Male	12	Fair
<b>Richtig 2007</b>	Case Report/Series	Austria	2	76	Female	63	Fair
<b>Zermani 2013</b>	Case Report/Series	Italy	1	41	Female	23	Fair
<b>Can 1997</b>	Case Report/Series	Turkey	1	22	Male	20	Fair
<b>Fleming 1941</b>	Case Report/Series	USA	1	54	Male	49	Good
<b>Anna 1984</b>	Case Report/Series		1	78	Female	-	Good
<b>Lee 2021</b>	Case Report/Series	Australia	1	67	Female	4	Good
<b>eastman2004</b>	Case Report/Series	USA	6	-	-	-	Bad
<b>Akay 2019</b>	Case Report/Series	Turkey	1	53	Male	51	Good

<b>Chadak 2020</b>	Case Report/Series	india	1	50	Female	30	Good
<b>Kargr 1996</b>	Case Report/Series	Turkey	1	38	Male	0.33	Bad
<b>Hagiawara 1996</b>	Case Report/Series	Japan	1	66	Female	63	Good
<b>Tofield 2001</b>	Case Report/Series	UK	1	25	Male	3	Fair
<b>Gul 2006</b>	Case Report/Series	Turkey	36	46	20 Males	32.2	Fair
<b>Onayemi 1996</b>	Case Report/Series	Nigeria	1	52	Male	22	Fair
<b>Hayakawa 1986</b>	Case Report/Series	Japan	1	45	Male	39	Bad
<b>Alconchel 1997</b>	Case Report/Series	Spain	1	46	Female	40	Good
<b>Cohney</b>	Case Report/Series	England	1	26	Female	63	Good
<b>Margolis 1970</b>	Case Report/Series	USA	1	26	Male	16	Good
<b>Bang 2017</b>	Case Report/Series	Korea	24	48	18 Males	31.6	Fair
<b>Bathelier 2006</b>	Case Report/Series	France	1	42	Male	30	Fair
<b>Yazici 2017</b>	Case Report/Series	Turkey	1	63	Female	35	Good
<b>Copcu 2003</b>	Case Report/Series	Turkey	31	39	21 Males	19	Fair
<b>Okamoto 2009</b>	Case Report/Series	Japan	1	64	Male	-	Bad
<b>Kikuchi 2003</b>	Case Report/Series	Japan	3	66	1 Male	51.47	Fair

<b>Burdach 2019</b>	Case Report/Series	Poland	1	77	Male	72	Fair
<b>sasaki 1998</b>	Case Report/Series	Japan	1	71	Female	70.34	Good
<b>Darzi 1992</b>	Case Report/Series	India	1	28	Female	26	Good
<b>zhao 2019</b>	Case Report/Series	China	15	19.13	10 Males	-	Fair
<b>Ko 1996</b>	Case Report/Series	Japan	2	58	Male	23.5	Good
<b>Ishiguro 2021</b>	Case Report/Series	Japan	2	48	Male	-	Good
<b>Horch 2005</b>	Case Report/Series	Germany	1	63	Male	58	Good
<b>Hannah 2019</b>	Case Report/Series	USA	1	late 30s	Female	3	Good
<b>Copcu 2005</b>	Case Report/Series	Turkey	1	74	Female	69	Fair
<b>Ikegawa 1989</b>	Case Report/Series	Japan	2	59.5	1 Male	50.5	Good